Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Corvus Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Corvus Pharmaceuticals, Inc.

CRVS

Corvus Pharmaceuticals, Inc.

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immuno-oncology and immune-mediated disease therapies. Its pipeline includes oral small molecules and monoclonal antibodies aimed at modulating immune cell signaling pathways, such as ITK inhibitors and adenosine receptor antagonists. The company targets cancers and inflammatory diseases, leveraging proprietary technology, strategic collaborations, and a focus on precision immune modulation to address large unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Corvus Pharmaceuticals, Inc.

1
1
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals Reports $13.7 Million Net Loss in Q1 2026 Amid Increased R&D Expenses

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals Reports $15.3 Million Net Loss for 2025, Focuses on Product Development

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals Reports $10.2 Million Net Loss, Sees Improvement in Financial Position

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals Reports $8M Net Loss in Q2 2025, Strengthens Financial Position

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals Reports $15.2 Million Net Income in Q1 2025, Driven by Warrant Liabilities Gain

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals Reports $62.3 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals Reports Significant Financial Changes, Net Loss Increases to $40.2 Million in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments